All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Topline results from the real-world study of ORG-101 for CD19+ B-ALL
On August 29, 2024, positive topline results were announced from the real-world study of ORG-101, a CD19 chimeric antigen receptor (CAR) T-cell therapy, for the treatment of CD19+ acute lymphoblastic leukemia (B-cell ALL).
Topline efficacy and safety data
- Data from 233 patients treated in the real-world setting in China were included.
- Following ORG-101 infusion, complete response rate was 82% in adult patients and 93% in pediatric patients.
- Compared with existing CAR T-cell therapies, the incidence of severe cytokine release syndrome was low; 2% in adult patients and 6% in pediatric patients.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with B-cell acute lymphoblastic leukemia do you see in a year?